Drug Approval | March 21, 2022
Zydus receives PAS approval for Mycophenolate Mofetil
The drug is indicated for use in combination with other drugs
The drug is indicated for use in combination with other drugs
The company plans to establish a state-of-the-art greenfield pharma facility with a total of 4-6 manufacturing units in different therapeutics categories to cater to domestic and export markets
The large-scale production of PhytoChol in Hanau, Germany, will meet an increased market demand for cholesterol
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
The stability is led by healthy demand in the domestic and emerging markets
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
Going forward, the fastest-growing regions in the generic pharmaceuticals market will be South America and the Middle East, where growth will be at CAGRs of 10.1% and 9.4% respectively
For the six months ended September 30, 2021, Lyka had reported revenues of Rs 109.87 crore
Subscribe To Our Newsletter & Stay Updated
